drugset / Trial / NCT05768347
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
Phase 1
Active not recruiting
9 enrolled
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).
Timeline
- Start
- 2023-08-10
- Primary completion
- 2025-10-10
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 3.2e+08 cells | Intravenous |